ASEAN Six-Market and India Post-Market Compliance Comparison

1. Key takeaways

Across the seven Asian markets that GRZAN serves on a long-term basis, India stands apart on three dimensions: fees are legislated in US dollars (most other markets charge in local currency), the licence is permanently valid (most markets use 3–5 year validity periods), and the vigilance reporting deadline is uniformly 15 days (some markets use a three-tier system of 48 hours, 10 days and 30 days). None of these features is unusual in isolation, but the combination shapes how a multi-market regulatory programme should be budgeted, diarised and staffed, and treating India as just one of seven similar filings is the most common planning error.

• The competent authority in India is the CDSCO, operating through a two-level structure of the CLA and the SLA.
• India classifies devices as Class A/B/C/D, as do Malaysia, Indonesia, Vietnam, Singapore and the Philippines in their own A–D schemes, while Thailand uses Class 1–4.
• The statutory import review period in India is 9 months under Rule 36(1), against widely varying periods elsewhere, from 10 working days to 6–12 months.
• Import fees are set in US dollars while manufacturing fees are in rupees; most other markets price in local currency.
• The Indian licence is permanently valid with a 5-year retention fee under Rule 37; Singapore is the closest comparator with permanent validity plus an annual retention fee.

2. Legal basis

The table below compares the current system features of each market on the dimensions that matter most for post-market planning. India’s column rests on the MDR 2017 and CDSCO FAQ material; the comparator column summarises the six other markets at the level of their published systems, with each market’s details covered in GRZAN’s dedicated country series.

The table is deliberately organised so that the Indian column can be read against all six comparators at once. Read vertically, it shows which features are shared and which are Indian outliers; read horizontally, it shows what a dossier prepared for one market can and cannot inherit when it moves to the next.

3. Expert insights

Insight one: permanent validity is rare in the region, and India’s version has teeth. It is conceptually closest to Singapore’s model of no fixed validity plus an annual retention fee, but India’s retention cycle is 5 years and the consequence of missing it is deemed automatic cancellation, which is harder than most markets. A permanently valid licence that lapses by administrative inattention is therefore a live operational risk, not a theoretical one: the certificate does not expire on a date anyone is watching, and the failure mode is silence followed by cancellation rather than a renewal notice.

Insight two: a uniform 15-day deadline is easier to get wrong than a three-tier system. The three-tier structure (48 hours, 10 days, 30 days) at least gives the company an explicit severity grading to work with. India’s single 15-day deadline looks simpler but in fact demands that the company completes its judgement and its submission for any event within 15 days, which places a higher demand on internal process rather than a lower one. There is no tier to hide behind: the clock is identical for a minor complaint and for a fatality, and the process must be fast enough for the worst case.

Insight three: dollar-denominated fees are a structural feature of the Indian system. They make Indian official fees sensitive to exchange rates, but they also let international companies compare budgets directly in dollar terms across their global portfolio. For a multi-market programme, this removes one layer of currency conversion from the planning model — the Indian column can be aggregated with US and other dollar-based filings without rate assumptions, while local-currency markets cannot.

Insight four: the six-country list is India’s own hard threshold. Other markets generally treat a foreign approval as something that can accelerate or simplify a filing; India’s Rule 36(3) list is different in kind — without a free sale certificate from one of the six listed reference countries, the device must go through local clinical investigation. The distinction between an accelerant and a prerequisite is exactly the distinction that changes project sequencing, and it is why the Indian clinical-evidence threshold must be assessed separately from every other market in the programme.

4. Practical recommendations

• In multi-market access planning, classify the seven markets by the nature of the threshold rather than by country: thresholds lying in clinical evidence (India, and markets requiring local clinical data), thresholds lying in the local entity (markets requiring a local licence holder), and thresholds lying in the document legalisation chain (markets requiring notarisation plus apostille or an equivalent certificate).
• Once classified this way, allocate resources by threshold type, because within seven markets for the same product, the real bottleneck is usually only one or two markets, and the remainder can proceed in parallel.
• Assess India’s six-country-list threshold on its own, before the dossier work starts, because it determines whether a local clinical study enters the plan at all.
• Enter the retention and renewal milestones of every market into a single register, with India’s 5-year retention date and 90-day grace period flagged against the deemed-cancellation consequence.
• Set the vigilance deadline separately for each market, with India set at a uniform 15 days, and budget the fee lines with India’s dollar denomination kept distinct from local-currency markets.

The classification habit is what makes the seven-market programme manageable: it converts seven country names into three threshold types, and the team’s effort then flows to the one or two markets that actually gate the launch instead of being spread evenly across filings that were never the constraint.

5. Verification checklist

• ☐ The plan has been classified by threshold nature rather than by country
• ☐ India’s six-country-list threshold has been assessed separately
• ☐ The retention and renewal milestones of every market have been entered in a single register
• ☐ Vigilance deadlines have been set per market, with India at a uniform 15 days
• ☐ The fee budget reflects India’s dollar denomination

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com